Related Experiment Video
Updated: Sep 8, 2025
An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants
Published on: May 22, 2020
Exploring the characteristics and most bothersome symptoms in MECP2 duplication syndrome to pave the path toward
Muharrem Ak1, Bernhard Suter1,2, Zekeriya Akturk3
1Section of Pediatric Neurology and Developmental Neuroscience, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Background:
MECP2 Duplication Syndrome (MDS), resulting from the duplication of Xq28 region, including MECP2, is a rare disorder with a nascent understanding in clinical features and severity. Studies using antisense oligonucleotides revealed a broad phenotypic rescue in transgenic mice. With human clinical trials on the horizon, there is a need to develop clinical outcome measures for MDS.
Methods:
We surveyed caregivers of MDS individuals to explore the frequency and severity of MDS clinical features, and identify the most meaningful symptoms/domains that need to be included in the outcome measure scales.
Results:
A total of 101 responses were eligible for the survey. The top six most meaningful symptoms to caregivers in descending order included epilepsy, gross motor, fine motor, communication, infection, and constipation problems. Epilepsy was present in 58.4% of the subjects and 75% were drug-resistant, Furthermore, ~12% required intensive care unit (ICU) admission. Infections were present in 55% of the subjects, and one-fourth of them required ICU admission. Constipation was present in ~85% of the subjects and one-third required enemas/suppositories.
Conclusion:
Our study is one of the largest cohorts conducted on MDS individuals characterizing the frequency and severity of MDS symptoms. Additionally, these study results will contribute to establishing a foundation to develop parent-reported outcomes in MDS.
Insights
Caregivers identified epilepsy, motor, communication, and infection as key symptoms of MECP2 Duplication Syndrome (MDS). This research informs the development of outcome measures for MDS clinical trials.
Area of Science:
- Genetics
- Neurology
- Rare Diseases
Background:
- MECP2 Duplication Syndrome (MDS) is a rare Xq28 duplication disorder with limited understanding of clinical features and severity.
- Antisense oligonucleotide studies in mice showed phenotypic rescue, with human trials anticipated.
- Developing clinical outcome measures for MDS is crucial for advancing research and treatment.
Purpose of the Study:
- To survey caregivers of individuals with MDS to understand symptom frequency and severity.
- To identify the most meaningful symptoms and domains for inclusion in outcome measure scales for MDS.
Main Methods:
- A survey was distributed to caregivers of individuals diagnosed with MECP2 Duplication Syndrome.
- 101 eligible responses were analyzed to determine the prevalence and impact of various clinical features.
Main Results:
- Epilepsy (58.4%), infections (55%), and constipation (~85%) were highly prevalent.
- Epilepsy was frequently drug-resistant (75%), and both epilepsy and infections led to ICU admissions (~12% and ~25%, respectively).
- Constipation often required intervention (enemas/suppositories in one-third of cases).
Conclusions:
- This study represents one of the largest cohorts characterizing MDS symptoms and their severity.
- Findings provide a foundation for developing parent-reported outcome measures for MDS.
- Identifying key caregiver-reported symptoms is vital for future clinical trial outcome assessments.
